436 Studies Now Enrolling
Topiramate as a disease altering therapy for Cryptogenic Sensory Peripheral Neuropathy (CSPN)
Top-CSPN Study
| Sponsor: | NINDS |
| Enrolling: | Male and Female Patients |
| Study Length: | 96 Weeks |
| Clinic Visits: | 9 |
| IRB Number: | AAAR3453 |
| U.S. Govt. ID: | NCT02878798 |
| Contact: | Thomas Brannagan, III, MD: 212-305-0405 / tb2325@cumc.columbia.edu |
Additional Study Information:
This study is looking at using topiramate as a potential therapy for patients with cryptogenic sensory peripheral neuropathy. Patients who are randomized into the study will return to the clinic for follow up every 16 weeks. The total length of the study is 96 weeks.
This study is closed
